Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
- PMID: 18936492
- PMCID: PMC2575488
- DOI: 10.1073/pnas.0804812105
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
Abstract
A decrease in the abundance and biodiversity of intestinal bacteria within the dominant phylum Firmicutes has been observed repeatedly in Crohn disease (CD) patients. In this study, we determined the composition of the mucosa-associated microbiota of CD patients at the time of surgical resection and 6 months later using FISH analysis. We found that a reduction of a major member of Firmicutes, Faecalibacterium prausnitzii, is associated with a higher risk of postoperative recurrence of ileal CD. A lower proportion of F. prausnitzii on resected ileal Crohn mucosa also was associated with endoscopic recurrence at 6 months. To evaluate the immunomodulatory properties of F. prausnitzii we analyzed the anti-inflammatory effects of F. prausnitzii in both in vitro (cellular models) and in vivo [2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced] colitis in mice. In Caco-2 cells transfected with a reporter gene for NF-kappaB activity, F. prausnitzii had no effect on IL-1beta-induced NF-kappaB activity, whereas the supernatant abolished it. In vitro peripheral blood mononuclear cell stimulation by F. prausnitzii led to significantly lower IL-12 and IFN-gamma production levels and higher secretion of IL-10. Oral administration of either live F. prausnitzii or its supernatant markedly reduced the severity of TNBS colitis and tended to correct the dysbiosis associated with TNBS colitis, as demonstrated by real-time quantitative PCR (qPCR) analysis. F. prausnitzii exhibits anti-inflammatory effects on cellular and TNBS colitis models, partly due to secreted metabolites able to block NF-kappaB activation and IL-8 production. These results suggest that counterbalancing dysbiosis using F. prausnitzii as a probiotic is a promising strategy in CD treatment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Comment in
-
Dynamic interfaces in an organic thin film.Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16418-25. doi: 10.1073/pnas.0805811105. Epub 2008 Sep 2. Proc Natl Acad Sci U S A. 2008. PMID: 18765797 Free PMC article.
-
From infection to colonization: the role of microbiota in transplantation.Am J Transplant. 2013 Apr;13(4):829. doi: 10.1111/ajt.12232. Am J Transplant. 2013. PMID: 23551627 Free PMC article. No abstract available.
Similar articles
-
Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis.J Crohns Colitis. 2013 Dec;7(11):e558-68. doi: 10.1016/j.crohns.2013.04.002. Epub 2013 May 2. J Crohns Colitis. 2013. PMID: 23643066
-
Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.Gut. 2016 Mar;65(3):415-425. doi: 10.1136/gutjnl-2014-307649. Epub 2015 Jun 4. Gut. 2016. PMID: 26045134 Free PMC article.
-
The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models.Inflamm Bowel Dis. 2014 Mar;20(3):417-30. doi: 10.1097/01.MIB.0000440815.76627.64. Inflamm Bowel Dis. 2014. PMID: 24418903
-
Faecalibacterium prausnitzii and human intestinal health.Curr Opin Microbiol. 2013 Jun;16(3):255-61. doi: 10.1016/j.mib.2013.06.003. Epub 2013 Jul 3. Curr Opin Microbiol. 2013. PMID: 23831042 Review.
-
Action and function of Faecalibacterium prausnitzii in health and disease.Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):643-648. doi: 10.1016/j.bpg.2017.09.011. Epub 2017 Sep 18. Best Pract Res Clin Gastroenterol. 2017. PMID: 29566907 Review.
Cited by
-
Immunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases.J Crohns Colitis. 2021 Nov 8;15(11):1959-1973. doi: 10.1093/ecco-jcc/jjab085. J Crohns Colitis. 2021. PMID: 33959743 Free PMC article.
-
Histone deacetylase inhibition and dietary short-chain Fatty acids.ISRN Allergy. 2011 Dec 26;2011:869647. doi: 10.5402/2011/869647. Print 2011. ISRN Allergy. 2011. PMID: 23724235 Free PMC article.
-
A Phase II Randomized Clinical Trial and Mechanistic Studies Using Improved Probiotics to Prevent Oral Mucositis Induced by Concurrent Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma.Front Immunol. 2021 Mar 24;12:618150. doi: 10.3389/fimmu.2021.618150. eCollection 2021. Front Immunol. 2021. PMID: 33841399 Free PMC article. Clinical Trial.
-
Cytomegalovirus infection disrupts the influence of short-chain fatty acid producers on Treg/Th17 balance.Microbiome. 2022 Oct 10;10(1):168. doi: 10.1186/s40168-022-01355-3. Microbiome. 2022. PMID: 36210471 Free PMC article.
-
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia.Nat Commun. 2022 Nov 1;13(1):5926. doi: 10.1038/s41467-022-33395-6. Nat Commun. 2022. PMID: 36319618 Free PMC article.
References
-
- Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517. - PubMed
-
- Seksik P, et al. Review article: The role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:11–18. - PubMed
-
- Rutgeerts P, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991;338:771–774. - PubMed
-
- Darfeuille-Michaud A, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998;115:1405–1413. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
